HFPod Podcast Evaluation

Course Title for Certificate

Name*

First NameLast Name

Email*

example@example.com

What best describes your title?*

How many years have you been in practice?

1. Which of the following statement(s) is correct?*

a. Only 10-20% of HCM cases are identified clinicallyb. HCM mortality has not changed over timec. Clinical phenotypes of oHCM and HFpEF are quite similard. Mortality in HFpEF is increasing

2. What statement is correct about the pathophysiology and treatment of hypertrophic cardiomyopathy (HCM)?*

a. In HCM, the most common genetic variants affect mitochondria.b. In HCM, genetic variants often reduce force of contraction at the myofilaments.c. Cardiac myosin inhibitors stabilize the so-called "super-relaxed state" (SRX) of myofilaments and thereby, reduce contractility.d. In animal models of HCM, the cardiac myosin inhibitor MYK-461 (i.e., mavacamten) increases force generation at the myofilaments.

3. According to the AHA/ACC 2024 guidelines for management of HCM, which is the recommended approach in patients with obstructive HCM and persistent symptoms despite treatment with betablockers?*

a. Start disopyramide, considering myosin inhibitors (CMI) as second line agents before resorting to invasive septal reduction therapies (SRT)b. Initiate a discussion regarding pharmacological options (CMIs or disopyramide) as an alternative to SRTc. Consider CMIs only if SRT faild. Consider initiating a combination of CMI and dosopyramide

How many patients do you currently see each month regarding obstructive hypertrophic cardiomyopathy?

Learning Objectives

Rows	Poor	Fair	Good	Very Good	Excellent
Examine the epidemiology, pathophysiology, and clinical presentation of oHCM in order to recognize and diagnose HCM accurately and in a timely manner
Analyze the most up to date diagnostic criteria and techniques in order to diagnose HCM accurately and in a timely manner
Evaluate current evidence-based, targeted treatments for oHCM, including CMIs, in order to update treatment plans and improve outcomes in patients with HCM
Incorporate practical application strategies for following evidence-based recommendations from guidelines for oHCM management in order to improve outcomes in patients with HCM

Please provide us with feedback regarding your experience at the activity:

Rows	Poor	Fair	Good	Very Good	Excellent
Overall
Content
Usefulness

Do you feel this activity was fair, balanced, and free of commercial bias?

YesNo

If no, please explain:

This educational activity will result in a change in my role as a healthcare team member.

YesNoN/A

Based on your participation in this activity, choose the statement(s) that applies to how your role as a healthcare team member will change:

I gained new strategies/skills/information that my team can apply to practiceI plan to implement new strategies/skills/information in my practiceI will be more competent in my team’s management of patient careI will improve my communication with the healthcare team

What factors beyond clinical care that effect the health of your patients does your team experience?

Attestation:

AcademicCME designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits^TM. Participants should claim only the credit commensurate with the extent of their participation in the activity.

Through an agreement between the American Medical Association and the Union
Européenne des Médecins Spécialistes, physicians may convert AMA PRA Category 1 Credit™ to an equivalent number of European CME Credits® (ECMECs®). These
credits will be recognized by all National Accreditation Authorities in Europe with which the UEMS has a signed agreement of recognition of credits.

Date

Credits